<DOC>
<DOCNO>EP-0610322</DOCNO> 
<TEXT>
<INVENTION-TITLE>
HELICOBACTER PYLORI GENES NECESSARY FOR THE REGULATION AND MATURATION OF UREASE, AND USE THEREOF
</INVENTION-TITLE>
<CLASSIFICATIONS>C12R101	A61K39106	C12N978	A61K3800	C12Q168	C07K1640	C12N1509	A61P3500	C12P2108	C12N121	C12N1531	A61K39106	C12P2108	C12N1531	C12N980	A61P100	C12Q168	A61P3500	C12N121	A61P3100	A61P104	A61P3104	C07K14195	C07K1640	C07K14205	C07K14195	C12N1509	A61K3800	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C12R	A61K	C12N	A61K	C12Q	C07K	C12N	A61P	C12P	C12N	C12N	A61K	C12P	C12N	C12N	A61P	C12Q	A61P	C12N	A61P	A61P	A61P	C07K	C07K	C07K	C07K	C12N	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C12R1	A61K39	C12N9	A61K38	C12Q1	C07K16	C12N15	A61P35	C12P21	C12N1	C12N15	A61K39	C12P21	C12N15	C12N9	A61P1	C12Q1	A61P35	C12N1	A61P31	A61P1	A61P31	C07K14	C07K16	C07K14	C07K14	C12N15	A61K38	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
A nucleotide sequence, 
characterized in that
 it is:

a) one or more nucleotide sequences constituted by genes termed 
ureE
, 
ureF
, 
ureG
,

ureH
 and 
ureI
 as shown in Figure 4; or
b) a sequence of at least 15 nucleotides encoding all or a portion of one of the
polypeptides UreE, UreF, UreG, UreH or UreI recognized by antibodies directed

against 
H. pylori
 or capable of behaving as a hapten or immunogen;
c) a sequence of at least 15 nucleotides homologous with a sequence of a 
ureE
, 
ureF
,

ureG
, 
ureH
 or 
ureI
 gene as defined in a) and hybridizing under stringent
conditions with said sequence, said homologous sequence being modified by

deletion, addition, substitution or inversion of one or more nucleotides such that
the polypeptide encoded by said modified sequence conserves the same

contribution to the formation of a functional urease in 
H. pylori
 as that observed
for the corresponding polypeptide encoded by the unmodified sequence of the


ureE
, 
ureF
, 
ureG
, 
ureH
 or 
ureI
 gene as expressed in 
H/ pylori
;
d) a complementary sequence of one of the nucleotide sequences defined in a), b) or
c).
A nucleotide sequence, 
characterized in that
 it is constituted by the ensemble of
nucleotide sequences for the genes 
ureE
, 
ureF
, 
ureG
, 
ureH
 and 
ureI
 as shown in
Figure 4 or the ensemble formed by variant nucleotide sequences corresponding to

said genes modified by deletion, addition, substitution or inversion of one or more

nucleotides, independently of each other, such that the ensemble of said variants
encodes polypeptides conserving the same contribution to the formation of a

functional urease in 
H. pylori
 as that observed with the ensemble of corresponding
polypeptides encoded by the unmodified sequences for the 
ureE
, 
ureF
, 
ureG
, 
ureH
 or 

ureI
 genes as expressed in 
H. pylori
, or a complementary sequence of one of the
sequences defined above.
A nucleotide sequence, 
characterized in that
 it is a sequence with a size of at least 15
nucleotides hybridizing under stringent conditions with a sequence of a 
ureE
, 
ureF
,

ureG
 or 
ureH
 gene in accordance with claim 1 or a complementary sequence thereof,
said sequence being modified by deletion, addition, substitution or inversion of one or

more nucleotides such that said sequence does not allow expression of a functional
urease in a strain of 
H. pylori
 mutated by allelic replacement of the wild type
sequence by said corresponding nucleotide sequence.
A nucleotide sequence according to claim 1 or claim 2, 
characterized in that
 it is
necessary for expression of functional urease in cells of 
E. coli
 previously
transformed with genes with structure 
ureA
, 
ureB
, 
ureC
 and 
ureD
.
A nucleotide sequence according to claim 3, 
characterized in that
 it is associated with
nucleic sequences corresponding to genes with structure 
ureA
 and 
ureB
 encoding
urease sub-units in 
H. pylori
.
A nucleotide sequence according to claim 3, 
characterized in that
 it is associated with
genes 
ureA
, 
ureB
, 
ureC
 and/or 
ureD
 encoding for urease in 
H. pylori
.
A nucleotide sequence according to claim 1 or claim 2, 
characterized in that
 it is the

ureE
 concatenation corresponding to nucleotides 800 to 1309 of the sequence of
Figure 4, or to any fragment of said concatenation provided that it hybridizes under

stringent conditions with the 
ureE
 concatenation or with the complementary
sequence.
A nucleotide sequence according to claim 1 or claim 2, 
characterized in that
 it is the

ureF
 sequence corresponding to nucleotides 1324 to 2091 of the sequence of Figure
4, or to any fragment of said concatenation provided that it hybridizes under stringent

conditions with the 
ureF
 concatenation or with the complementary sequence. 
A nucleotide sequence according to claim 1 or claim 2, 
characterized in that
 it is the

ureG
 concatenation corresponding to nucleotides 2123 to 2719 of the sequence of
Figure 4 or to any fragment of said concatenation provided that it hybridizes under

stringent conditions with the 
ureG
 concatenation or with the complementary
sequence.
A nucleotide sequence according to claim 1 or claim 2, 
characterized in that
 it is the

ureH
 concatenation corresponding to nucleotides 2722 to 3516 of the sequence of
Figure 4, or to any fragment of said concatenation provided that it hybridizes under

stringent conditions with the 
ureH
 concatenation or with the complementary
sequence.
A nucleotide sequence according to claim 1 or claim 2, 
characterized in that
 it is the

ureI
 concatenation corresponding to nucleotides 211 to 795 of the sequence of Figure
4, or to any fragment of said concatenation provided that it hybridizes under stringent

conditions with the 
ureI
 concatenation or with the complementary sequence.
A nucleotide sequence according to claim 7, 
characterized in that
 it is the following
nucleotide concatenation or 
in that
 it comprises said concatenation:

A nucleotide probe, 
characterized in that
 it is constituted by a nucleotide sequence
according to any one of claims 1 to 12, said sequence being labeled.
A nucleotide primer, 
characterized in that
 it comprises a nucleotide fragment of a
sequence according to any one of claims 1 to 12, said fragment comprising about 18

to about 30, preferably about 25 to about 30 nucleotides, and is capable of
hybridizing to the 5' and 3' ends of a specific nucleotide fragment of at least one gene

selected from 
ureE
, 
ureF
, 
ureG
 or 
ureH
 for use in a gene amplification reaction.
Use of a primer according to claim 14, for 
in vitro
 detection of an infection with 
H.
pylori
, in a biological sample and following gene amplification reactions. 
Use of a probe according to claim 13, for in vitro detection in a biological sample of
an infection with H. pylori, if necessary following gene amplification reactions.
A polypeptide, 
characterized in that
 it is:

i) one of the polypeptides UreE, UreF, UreG, UreH or UreI shown in Figure 4;
or
ii) all parts of at least one of the polypeptides defined in i) and conserving the
same contribution to the formation of a functional urease in 
H. pylori
 as that
observed for the corresponding unmodified polypeptides UreE, UreF, UreG,

UreH and UreI as expressed in 
H. pylori
;
iii) all parts of at least one of the polypeptides defined in i) recognized by
antibodies directed against 
H. pylori
 or capable of behaving as a hapten or
immunogen.
A polypeptide according to claim 17, modified by deletion, addition, substitution or
inversion of one or more amino acids provided that it conserves the same contribution

to the formation of a functional urease in 
H. pylori
 as that observed for the
polypeptides UreE, UreF, UreG, UreH and UreI as expressed in 
H. pylori
.
A recombinant vector, 
characterized in that
 it contains a sequence according to claim
3.
A recombinant vector according to claim 19, 
characterized in that
 it is a cosmid or a
plasmid.
A recombinant vector according to claim 19 or claim 20, 
characterized in that
 it is the
plasmid pILL753 contained in 
E. coli
 HB101 deposited at the CNCM on 3
rd
 October
1991 with accession number I-1148.
A recombinant vector according to claim 19 or claim 20, 
characterized in that
 it is the
plasmid pILL763 contained in 
E. coli
 HB101 deposited at the CNCM on 3
rd
 October
1991 with accession number I-1149.
 
A recombinant strain of 
H. pylori
, 
characterized in that
 it has a mutation in at least
one gene selected from genes 
ureE
, 
ureF
, 
ureG
, 
ureH
 or 
ureI
 shown in Figure 4, under
conditions such that the recombinant strain expresses a urease-negative phenotype or

exhibits attenuation of urease activity compared with the same non-mutated strain.
A recombinant strain of 
H. pylori
 according to claim 23, 
characterized in that
 it is
mutated at the 
ureG
 gene.
A recombinant strain of 
H. pylori
 according to claim 23 or claim 24, 
characterized in
that
 it is the mutated N6 strain (NCIMB nÂ° 40512).
A recombinant strain of 
H. pylori
 according to one of claims 23 to 25, 
characterized
in that
 it comprises a nucleotide sequence according to claim 3.
A recombinant strain of 
H. pylori
 according to claim 25, 
characterized in that
 it is a
N6 strain mutated in at least one of the 
ureE
, 
ureF
, 
ureG
, 
ureH
 or 
ureI
 genes by allelic
replacement of its wild type sequence by the corresponding modified sequence

according to claim 3, such that its urease activity is attenuated with respect to the
same non mutated strain.
A recombinant host cell different from 
H. pylori
, 
characterized in that
 it is
transformed by a sequence according to any one of claims 1 to 12 or a recombinant

vector according to one of claims 19 to 22, under conditions allowing its expression
in the host.
A recombinant host cell according to claim 28, 
characterized in that
 it is a
recombinant 
E. coli
 strain.
An immunogenic composition, 
characterized in that
 it contains a recombinant host
cell according to claim 28 or claim 29 or a recombinant strain of 
H. pylori
 according
to any one of claims 23 to 27.
A kit for 
in vitro
 diagnosis of any infection with 
H. pylori
 in a predetermined
biological sample, 
characterized in that
 it comprises: 

at least one pair of nucleotide primers according to claim 14 that are capable of
hybridizing to the 5' and 3' ends of a specific nucleotide fragment of at least one

gene selected from 
ureE
, 
ureF
, 
ureG
, 
ureH
 and 
ureI
;
reagents necessary for extracting nucleic acids from the treated sample;
reagents to carry out polymerization of said nucleotide fragment from nucleotide
primers, in particular polymerization enzymes in sufficient quantity to carry out

amplification of the fragment which is to be amplified;
at least one concatenation of nucleotides which can be used as a probe and which
is capable of hybridizing under predetermined conditions with the amplified

nucleotide fragment;
if appropriate, means for revealing hybridization.
A kit for 
in vitro
 diagnosis of an infection with 
H. pylori
, 
characterized in that
 it
comprises:


a predetermined quantity of a probe according to claim 13;
a suitable medium for carrying out a hybridization reaction between the nucleic
acid of 
H. pylori
 to be detected and the probe;
reagents for detecting any hybrids which are formed.
A polyclonal or monoclonal antibody, 
characterized in that
 it recognizes a
polypeptide according to claim 17 or claim 18.
A composition for treating an infection with 
H. pylori
, 
characterized in that
 it
contains an antibody according to claim 33.
A polypeptide constituted by the concatenation: Ala Lys Ile Cys Tyr Glu Ile Gly Asn
Arg His.
</CLAIMS>
</TEXT>
</DOC>
